Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study to Assess Lebrikizumab Pen Ease of Use in Patients With Atopic Dermatitis

NCT06444165 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT06444165
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06444165 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study to Assess Lebrikizumab Pen Ease of Use in Patients With Atopic Dermatitis
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
June 4, 2024
Completion date
June 10, 2024
Enrollment
55 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis